SCHEMBL2096573

SCHEMBL2096573

COc1c(-c2ccccc2)cc(-c2ccccc2)cc1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 4/20 0.55
PDE4A P27815 3/20 0.55
PDE4C Q08493 3/20 0.55
PDE4D Q08499 3/20 0.55
IKBKB O14920 1/20 0.54
FYN P06241 1/20 0.46
BACE1 P56817 5/20 0.44
SQOR Q9Y6N5 1/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
MITF O75030 1/20 0.42
HTT P42858 1/20 0.42
PTPN1 P18031 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12325398 0.98 PDE4B (0.56) PDE4BPDE4APDE4CPDE4DIKBKB
SCHEMBL7169549 0.86 IKBKB (0.48) PDE4BPDE4APDE4CPDE4DIKBKB
SCHEMBL12455941 0.85 PDE4B (0.46) PDE4BPDE4APDE4CPDE4DIKBKB
SCHEMBL757781 0.84 PDE4B (0.53) PDE4BPDE4APDE4CPDE4DIKBKB
SCHEMBL24238256 0.83 PDE4B (0.56) PDE4BPDE4APDE4CPDE4DIKBKB
SCHEMBL29113865 0.83 PDE4B (0.51) PDE4BPDE4APDE4CPDE4DIKBKB
SCHEMBL3686460 0.83 BACE1 (0.62) PDE4BPDE4APDE4CPDE4DBACE1
SCHEMBL25913140 0.83 PDE4B (0.51) PDE4BPDE4APDE4CPDE4DIKBKB
SCHEMBL12299729 0.83 PDE4B (0.51) PDE4BPDE4APDE4CPDE4DIKBKB
SCHEMBL19750886 0.83 CYP1A1 (0.47) PDE4BPDE4APDE4CPDE4DIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779911-B2 Production of fatty olefin derivatives via olefin metathesis PROVIVI, INC. (US) 2023-10-10 US disclosed
US-20220032280-A1 PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS PROVIVI, INC. (US) 2022-02-03 US disclosed
EP-2771386-B1 HYPERBRANCHED POLYMERS, METHODS FOR PRODUCING SAME, AND USE OF SAME IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2017-03-01 EP disclosed
EP-2566875-B1 FORMULATIONS AND ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-01-06 EP disclosed
EP-2517277-B1 COMPOSITION FOR THE PREPARATION OF ORGANIC ELECTRONIC (OE) DEVICES MERCK PATENT GMBH (DE) 2015-07-08 EP disclosed
WO-2015018480-A1 FORMULATION FOR THE PREPARATION OF ORGANIC ELECTRONIC (OE) DEVICES COMPRISING A POLYMERIC BINDER MERCK PATENT GMBH (DE) 2015-02-12 WO disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
WO-2011137922-A1 FORMULATIONS AND ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2011-11-10 WO disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 PDE4B 2685/4885PDE4A 3611/4885PDE4C 3847/4885
US-11779911-B2 Production of fatty olefin derivatives via olefin metathesis SREBF1, F2, SREBF2 PDE4B 4120/4885PDE4A 4491/4885PDE4C 4323/4885
US-20220032280-A1 PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS SREBF1, F2, SREBF2 PDE4B 4120/4885PDE4A 4491/4885PDE4C 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.